Mauro Provezza

Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy.

Rottapharm SpA engages in the research, development, manufacture, and marketing of pharmaceuticals and products for wellness and personal care. Its products are distributed through the following categories: Semi-ethical, which includes prescribed and non-reimbursed, non-reimbursed, and over-the-counter medicines, cosmetics, nutraceuticals, and medical equipment; Reimbursed pharmaceuticals; and Natural extracts, which carry the brand Euromed. The company was founded by Luigi Rovati in 1961 and is headquartered in Milan, Italy.

Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom.

Axon Partners Group Investment SGEIC SA (Axon Partners Group) is a private equity and venture capital firm founded in 2006 by Julio Villalobos Rius. The firm is headquartered in Madrid, Spain with offices across the globe.

Xyence Capital SGR (Xyence Capital) is a venture capital firm founded in 2002 by Stefano Peroncini and Pierluigi Paracchi. The firm is headquartered in Milano, Italy.

Genextra SpA (Genextra) is a venture capital firm founded in 2004 by Franceso Micheli and Saverio Minucci. The firm is headquartered in Milan, Italy.

EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy.

Fondazione Toscana Life Sciences is a non-profit organization founded by and composed of public and private institutions. These institutions encompass banks, universities, provincial, municipal and educational entities. The organization was founded in 2004 and is headquartered in Sienna, Italy.

Fidim Srl operates as a holding company. The company is headquartered in Monza, Italy.

Sanofi SpA engages in the research, production, and distribution of pharmaceuticals. It provides solutions for the treatment of diseases in various medical fields such as cardiovascular, diabetes, oncology and blood cancers, nephrology, equivalent medicines, rare diseases, and multiple sclerosis as well as develops vaccines. The company was founded in 1973 and is headquartered in Milan, Italy.

AbbVie Srl is a biopharmaceutical company. It manufactures and distributes pharmaceutical products. The company is headquartered in Campoverde di Aprilia, Italy.

Panakes Partners Sgr SpA (Panakes Partners) is a venture capital firm founded in 2015 by Alessio Beverina, Fabrizio Landi and Diana Sareceni. The firm is headquartered in Milan, Italy.

Lipogems International SpA engages in the provision of adipose tissue solutions for pathologies, orthopedics, general surgery, and wound care. It offers Lipogems system, a sterile single –use medical device for the closed-loop processing and transferring of autologous adipose tissue in a single surgical step. The company was founded by Carlo Tremolada in 2010 and is headquartered in Milan, Italy.

Rottapharm Biotech SRL operates as a drug research and development company. The company was founded in 1961 and is headquartered in Monza, Italy.

Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation.

Altheia Science Srl develop treatment and resolving medicines for auto-immune diseases, focusing on multiple sclerosis and diabetes. The company was founded by Paolo Fiorina, Alessandra Biffi, Paolo Rizzardi, and is headquartered in Milan, Italy.

InnovHeart Srl is a holding company, which engages in the development of transcatheter mitral valve replacement (TMVR) systems for the treatment of patients with mitral valve disease. It also develops Saturn Prosthesis, Transapical, and Transeptal systems that are designed to be consistent with the anatomy of the mitral valve. The company was founded by Giovanni Righini and is headquartered in Milan, Italy.

Aurora-TT Srl (AuroraTT) is an independent venture capital firm.. Guido Guidi, Gabriele Campi, Pierluigi Paracchi, Gian Paolo Maria Rizzardi and Edoardo Negroni founded the firm in 2017. The firm is headquartered in Milan, Italy.

Takis Srl is an Italian biotech company founded in November 2009 by a group of scientists from IRBM, a research center near Rome, Italy. Takis is based in Castel Romano, IT and has more than 10 years of experience in drug discovery, contributing to the validation of new targets for the treatment of chronic viral diseases and cancer, and to a number of IND/CSA filings in the areas of virology and oncology. The private company specializes in drug discovery in oncology and has expertise in vivo electro-gene-transfer, which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis' pipeline includes four cancer vaccine candidates based on this technology. The company was founded by Luigi Aurisicchio, who has been the CEO since incorporation.

Aurora Science, invests in Italian startups. The fund invests in health technology with particular interest for biotech and pharmaceuticals. It provides equity financing for early stage investing between EUR 1 to EUR 5 million.

Bio-Based Industries Consortium AISBL is a Belgian company that aims to make the bio-based industry in Europe innovative, sustainable, and competitive. The non-profit company is based in Brussels, Belgium. The company's vision is to lead a circular bio society by 2050. It was founded in 2013, and the CEO is Dirk Carrez.

Xgen Venture Sgr SpA (XGEN Venture) is a venture capital firm founded in 2021 by Federica Draghi, Paolo Fundarò and Daniele Scarinci. The firm is headquartered in Milan, Italy.

Part of Takeda Pharmaceutical Co., Ltd., Takeda France SAS is a company based in Paris, France. The CEOs are Anne-Sylvie Brunel, Sonia Rouges. Takeda France specializes in research and development for innovation in health, with expertise in gastroenterology, hematology, oncology, and rare diseases. The French company is committed to promoting information and studies requiring access to data by health manufacturers. Takeda France also has initiatives for diversity, equity, and inclusion, as well as a policy for the protection of personal data. The company was founded in 1978.